BEONE MEDICINES (06160) shares rose nearly 4% following its earnings release, trading up 3.66% at HK$206.8 as of press time, with a turnover of HK$362 million.
On August 6, the company reported its second-quarter 2026 results, with total global revenue reaching approximately $1.705 billion, up 30% year-over-year. GAAP net profit was about $237 million, a 151% increase, while adjusted net profit was roughly $444 million, up 76% year-over-year. Product revenue for the second quarter of 2026 stood at $1.7 billion, representing a 29% increase. BEONE MEDICINES's Brukinsa recorded global sales of $1.2 billion in the second quarter, up 31% year-over-year, with U.S. sales at $893 million, also a 31% increase. Tevimbra (tislelizumab) achieved global sales of $229 million in the second quarter, up 18% year-over-year. Licensed products from Amgen generated global sales of $157 million in the quarter, up 25% year-over-year.
CLSA noted in a research report that BEONE MEDICINES has made further progress in solid tumors. The GPC3 x 4-1BB bispecific antibody BGB-B2033 has completed a registrational expansion study in China for second-line hepatocellular carcinoma, with plans to initiate a global Phase 3 clinical trial for second-line liver cancer in the second half of the year. CLSA stated it remains positive on the company's strong global commercialization progress and the advancement of its novel solid tumor pipeline into later stages. In response to the performance and updated guidance, the firm raised its 2026 to 2028 sales forecasts by 4%, 3.3%, and 3.2%, respectively, and its net profit projections by 23.5%, 12.5%, and 7.3%.
Comments